Achillion Pharmaceuticals Inc. raised $41 million in a private round of financing that its CEO expects will allow it to take its lead anti-infective compound through Phase II trials and into Phase III before year’s end.
In what its chairman and CEO called a “transforming event” for the company, Atrix Laboratories Inc. received FDA approval for Eligard 7.5 mg, its one-month treatment for advanced prostate cancer.
In what its chairman and CEO called a “transforming event” for the company, Atrix Laboratories Inc. received FDA approval for Eligard 7.5 mg, its one-month treatment for advanced prostate cancer.
Cubist Pharmaceuticals Inc. said its investigational antibiotic, Cidecin, failed to meet its primary endpoint in the first of two pivotal Phase III trials for community-acquired pneumonia.
